ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma.
Abstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.Annals of surgical oncology · 2023Trial
- Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma.Cancer control : journal of the Moffitt Cancer CenterTrial
- Salvage Radiotherapy in Isolated Locoregional Recurrence of Pancreatic Adenocarcinoma Post-Radical Surgical Resection: Prudent or Pointless? A Retrospective Comparative Analysis.Current oncology (Toronto, Ont.) · 2026Article
- New implications from long-term outcomes of perioperative therapy in resectable pancreatic cancer.British journal of cancer · 2026Review
- Impact of adding recurrence/metastasis-directed therapy to systemic therapy in postoperative recurrent or metastatic pancreatic adenocarcinoma: a retrospective cohort study.Therapeutic advances in medical oncology · 2026Article
- Real-World Evidence of Porto-Mesenteric Vein Resections with Pancreatectomy and the Development of Predictive Clinical Nomograms for Postoperative Outcomes-An Analysis of 389 Cases: The "Porto-Mesenteric Vein Resection-Indian MulticentrE" (PRIME) Study.Annals of surgical oncology · 2025Observational
- Optimizing neoadjuvant chemoradiation in resectable and borderline resectable pancreatic cancer: Evidence-based insights.World journal of clinical oncology · 2025Review
- Evolving concepts in adjuvant/neoadjuvant therapy for resectable pancreas cancer.The Journal of clinical investigation · 2025Review
- Evolving survival patterns in pancreatic adenocarcinoma: a 23-year retrospective observational analysis.Journal of gastrointestinal oncology · 2025Article
- Endoscopic Ultrasound-Guided Brachytherapy of Yttrium-90 Implantation Into Pancreas: A Dose-Escalation Pilot Study.MedComm · 2025Article
- Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical exploration: multicentre, observational cohort study.The British journal of surgery · 2025Observational
- The Evolving Role of Neoadjuvant Radiation Therapy in Pancreatic Adenocarcinoma.Journal of clinical medicine · 2024Review
- Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design.Future oncology (London, England) · 2024Article
- Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2024Review
- Top Pancreatic Tumor Articles from 2021 to Inform Your Cancer Patients.Annals of surgical oncology · 2023Review
- Neoadjuvant therapy for pancreatic cancer.Nature reviews. Clinical oncology · 2023Review
- Article
- HNRNPC regulates RhoA to induce DNA damage repair and cancer-associated fibroblast activation causing radiation resistance in pancreatic cancer.Journal of cellular and molecular medicine · 2022Article
- Targeting STAT3 Signaling Facilitates Responsiveness of Pancreatic Cancer Cells to Chemoradiotherapy.Cancers · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
William A HallMedical College of Wisconsin, Department of Radiation Oncology and the LaBahn Pancreatic Cancer Program, Milwaukee, WI.ORCID 0000-0001-7017-6755
Laura A DawsonRadiation Medicine Program, Princess Margaret Cancer Centre; Department of Radiation Oncology, University of Toronto, Toronto, Canada.
Theodore S HongMassachusetts General Hospital, Department of Radiation Oncology, Boston, MA.ORCID 0000-0001-8481-6581
Manisha PaltaDuke University, Department of Radiation Oncology, Durham, NC.ORCID 0000-0002-9085-9075
Joseph M HermanNorthwell Health, Department of Radiation Oncology, New Hyde Park, NY.
Douglas B EvansMedical College of Wisconsin, Department of Surgery and the LaBahn Pancreatic Cancer Program, Milwaukee, WI.ORCID 0000-0001-5708-467X
Susan TsaiMedical College of Wisconsin, Department of Surgery and the LaBahn Pancreatic Cancer Program, Milwaukee, WI.
Cristina R FerroneMassachusetts General Hospital, Department of Surgery, Boston, MA.
Jason B FlemingMoffitt Cancer Center, Department of Surgery, Tampa, FL.ORCID 0000-0002-8796-5627
Daniel T ChangStanford Health Care, Department of Radiation Oncology, Stanford, CA.ORCID 0000-0003-2760-1554
Christopher CraneMemorial Sloan-Kettering Cancer Center, Department of Radiation Oncology, New York, NY.
Albert C KoongMD Anderson Cancer Center, Department of Radiation Oncology, Houston, TX.ORCID 0000-0001-9824-1643
Andrew OarGold Coast University Hospital, Gold Coast, Queensland, Australia.
Parag ParikhHenry Ford Health System, Department of Radiation Oncology, Detroit, MI.
Beth EricksonMedical College of Wisconsin, Department of Radiation Oncology and the LaBahn Pancreatic Cancer Program, Milwaukee, WI.
Sarah HoffeMoffitt Cancer Center, Department of Surgery, Tampa, FL.
Karyn A GoodmanMount Sinai Hospital, Department of Radiation Oncology, New York, NY.ORCID 0000-0002-4576-6355
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4MInstitutional Career Development CoreKL2TR001438 · NCATS · MEDICAL COLLEGE OF WISCONSIN · PI WIDLANSKY, MICHAEL E · 2015 to 2024
$2.9MNCATS NIH HHS KL2 TR001438NCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenocarcinomaFemaleHumansMalePancreatic NeoplasmsRadiosurgery
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.